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Assessment of Therapy Responses and Prediction of
Survival in Malignant Pleural Mesothelioma Through
Computer-Aided Volumetric Measurement on Computed
Tomography Scans
Fan Liu, PhD,* Binsheng Zhao, DSc,† Lee M. Krug, MD,‡ Nicole M. Ishill, MS,††
Remy C. Lim, MD, Pingzhen Guo, MD,¶ Matthew Gorski, BA,# Raja Flores, MD,**
Chaya S. Moskowitz, PhD,†† Valerie W. Rusch, MD,** and Lawrence H. Schwartz, MD¶
Purpose: The purposes of this study were (1) to calculate the tumor
volume in patients with malignant pleural mesothelioma using
computed tomography (CT) scan images and a computer-aided
measurement technique and (2) to investigate whether the baseline
volume, or volume change after chemotherapy, predicts patient
survival.
Methods: We compiled the clinical characteristics and outcome
from 30 patients enrolled in two clinical trials at our cancer center in
which the patients were treated with induction chemotherapy fol-
lowed by surgery and radiation. CT scans of 30 patients were
obtained at baseline and after two cycles of chemotherapy. Tumor
volumes were calculated using a semiautomated computer algo-
rithm. Overall survival was measured using a landmark time at 3
months post-treatment start date such that all patients had already
received two cycles of chemotherapy and a follow-up scan. Asso-
ciation of volume changes with overall survival were determined by
a Cox Proportional Hazards Model or log-rank test. The relationship
between both pre and postoperative clinical stage and baseline tumor
volume was analyzed using the rank sum test.
Results: The median baseline tumor volume was 473 cm3 (range, 61
cm3–2108 cm3). Patients with high preoperative stages (III and IV)
had larger baseline tumor volume than those with low preoperative
stages (I and II) (p  0.05). Patients with baseline volumes smaller
than 619 cm3 tended to survive longer than those with baseline
volumes larger than or equal to 619 cm3 (p  0.07). Percentage
change of tumor volume from baseline to first follow-up CT after
two cycles of chemotherapy was significantly associated with over-
all survival (hazard ratio: 1.94 [95% confidence interval, 1.05–3.60],
p  0.04). Whereas the relative change in modified RECIST
measurements was not significantly associated with overall survival
(hazard ratio: 1.06 [95% confidence interval, 0.96–1.16], p  0.25).
By classifying changes of tumor volumes between two scans into
two groups, i.e., “increase” and “decrease,” a significant difference
in survival was found between those who increased and decreased
after two cycles of chemotherapy (p  0.03).
Conclusions: Changes in tumor volume after two cycles of
chemotherapy predicted overall survival in patients with malig-
nant pleural mesothelioma. Tumor volume at baseline was shown
to be associated with preoperative clinical stage and survival.
Computer-aided volumetric measurements may enable more re-
liable therapeutic response assessment and could provide addi-
tional prognostic information.
Key Words: Malignant pleural mesothelioma, Therapy response
assessment, Chest CT, Tumor volume, Image segmentation.
(J Thorac Oncol. 2010;5: 879–884)
Malignant pleural mesothelioma (MPM) is an aggressiveprimary tumor with a well-established link to asbestos
exposure.1 It was predicted that number of deaths of MPM
would be 72,000 in the next 40 years in the United States, and
the mortality rate is increasing worldwide.2 Most patients
present with disease involving the entire ipsilateral pleura,
however, there is no universally accepted standard therapy
for patients with locally advanced disease. The results
from multiple studies using a multimodality approach to
MPM, including surgery, chemotherapy, and radiation,
have been encouraging.3,4 They have sparked enthusiasm
to investigate new drugs to improve patients’ survival.
Finding the optimal therapy and methodology for accu-
rately gauging response to these therapies is therefore key
and of great clinical importance.
Computed tomography (CT) has been the primary im-
aging modality for diagnosis, staging, and response assess-
ment of MPM because of its ability to provide anatomic
details of both normal and abnormal structures, its wide
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availability, and relatively low cost.5–8 For therapeutic re-
sponse assessment, the bidimensional World Health Organi-
zation criteria9 and the simplified unidimensional RECIST
criteria10 are considered the gold standard in clinical practice
and clinical trials. However, MPM typically spreads as a rind
around the pleura, which prevents standard linear tumor
measurements (Figure 1). This particularly complicates the
ability to measure the extent of disease and the response to
therapy—an issue in both standard clinical practice and when
conducting clinical trials. Studies have shown the inadequacy
of the standard RECIST criteria in the assessment of thera-
peutic response in MPM.11–13 The recently modified RE-
CIST criteria, which recommend measuring tumor thick-
ness at a location perpendicular to chest wall or
mediastinum, have been published and are being used in
clinical trials, aiming at improving response assessment in
MPM.14 Nonetheless, the linear measurement is not able to
faithfully capture the change in tumor burden and lacking
in reproducibility because of the circumferential and axial
growing patterns of MPM.15
Preliminary data by Pass et al. demonstrate that preop-
erative tumor volume is predictive of overall and progression-
free survival. Similarly, post resection residual tumor burden
predicts outcome.16,17 The tumor volumes in the study by
Pass et al., however, were obtained by manually delineating
tumor contours—an extremely time consuming procedure.
Ceresoli et al.12 highlight the importance of computer-as-
sisted CT techniques for response assessment. To date, auto-
mated/semiautomated tools for the identification and quanti-
fication of tumor volumes have not been validated for
therapeutic assessment and clinical and prognostic use.
In this study, we applied a semiautomatic three dimen-
sional computer method18 to assist in the measurement of
tumor volumes on serial CT scans retrieved from two clinical
trials. The purposes of our study were to investigate whether
the MPM volumes on baseline study or volume changes after
chemotherapy would associate with patient survival, and
whether the volumetric technique would have any advantage
over the modified RECIST measurement.
PATIENTS AND METHODS
Patients
Imaging and clinical data from 30 patients were retro-
spectively collected from two Institutional Review Board
approved, HIPPA compliant phase II clinical trials that were
performed at our referral-based cancer center.4,19 In both of
these studies, patients received up to four cycles of induction
chemotherapy (gemcitabine/cisplatin or pemetrexed/cispla-
tin). Those patients without disease progression were then
referred for resection by extrapleural pneumonectomy fol-
lowed by postoperative hemithoracic radiation. CT scanning
was performed to assess response to chemotherapy after
every two treatment cycles. All patients in the two protocols
received the same therapy, regardless of their MPM volumes.
CT images were acquired from a LightSpeed QX/I,
LightSpeed16, and a HiSpeed CT/I (GE Medical Systems,
Milwaukee, WI), using the standard contrast-enhanced diag-
nostic imaging technique (current: 180 mA–440 mA, Pitch:
0.938–1.5, Tube rotation speed: 0.5 seconds rotation, recon-
struction: Lung algorithm, 120 kvp). Slice thicknesses were 5
mm (n  32), 7 mm (n  1) or 7.5 mm (n  24) without
overlapping.
Computer-Aided Tumor Volume Quantification
A semiautomatic computer method was used to assist in
the identification and segmentation of tumor volumes that
were associated with MPM.18 The method used a sequential
segmentation strategy to “dissect” MPM from surrounding
normal organs/tissues such as chest wall, liver, and spleen, by
combining different image processing techniques including a
chest-rib interpolation and the gradient vector flow snake.18,20
The MPM was then segmented from the heart, stomach and
lung parenchyma using a multiple thresholding technique. To
ensure correctness and consistency of MPM volumes, com-
puter-generated tumor contours on baseline and follow-up
scans were side-by-side displayed and carefully reviewed by
a thoracic radiologist with 25 years of experience in chest CT
interpretation. Suboptimal computer results were corrected
by the radiologist with the help of an imaging viewer system
developed in our research group (Figure 2). To study inter-
radiologists’ measurement variation, a second radiologist (a
radiology fellow in body imaging with 5 years experience)
independently edited the computer results, also in a side-by-
side way.
Statistical Methods
Overall survival was measured from day 1 of the
treatment until death or the last follow-up. The survival
curves were computed using the Kaplan-Meier method.21
Overall survival from the baseline and the follow-up mea-
surements were analyzed separately. In the baseline analysis,
to determine the optimal cut point for tumor volume in
predicting patient survival, a minimum p value approach was
FIGURE 1. Circumferential and irregular shape of malig-
nant pleural mesothelioma showed limitations of 2D mea-
surement (arrows).
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used.22 In the analysis using measurements from follow-up
scans, a landmark analysis was performed at 3 months, as this
was the time point by when the first follow-up scans should
have been performed. Changes in volumes and modified
RECIST measurements between the baseline and follow-up
scans were computed using the percent relative change. The
association between the relative changes in these measure-
ments and overall survival were determined using Cox Pro-
portional Hazards Regression.23 Their predictive accuracies
were quantified using the C-Index,24 and indices were com-
pared. A C-index is interpreted in the same way as an area
under the curve, where 0.5 indicates the method is as efficient
as flipping a coin, and values of 1.0 indicate perfect predic-
tion. To determine whether there was any relationship be-
tween preoperative and postoperative clinical stages (using
the International Mesothelioma Interest Group criteria25) and
baseline CT volume, we collapsed stage into high (stages III
and IV) and low (stages I and II) based on tumor, node,
metastasis (TNM) staging criteria. The distribution of vari-
ables by stage was evaluated using the rank sum test.26
Interobserver variability was assessed using the Concordance
Correlation Coefficient (CCC).27 Perfect agreement between
radiologists is signified by a CCC equal to one and no
agreement between radiologists is signified by a CCC equal
to zero. Values of the CCC close to one imply very good
agreement. Statistical significance was identified at the 5%
level. All analyses were conducted using SAS 9.2 for Win-
dows (SAS, Cary, NC) or the Hmisc package in R.
RESULTS
Overall Survivals
Thirty MPM patients were included in this analysis, 23
males and seven females. The age of the patients ranged from
34 to 76 with an average of 60 years old. MPM were
pathologically proven. Most patients (n  23) had surgery
after chemotherapy. Among these patients, 27 had one fol-
low-up scan performed after two cycles of treatment (2–6
weeks, median 5 weeks).
The median overall survival was 16 months. There
were 26 deaths with median survival of 13.2 months (range,
3.3–47.4), while the four survivors have a median follow-up
of 36.1 months (range, 17.4–49.5). The overall survival
curve was shown in Figure 3.
Baseline Analysis
On baseline scans, the mean MPM volume was 596 
520 cm3 (range, 61 cm3–2108 cm3; median, 473 cm3). A
threshold, 618.49 cm3 in our study determined by the mini-
mum p value approach, was applied to separate patients into
two categories: the group with larger tumor volumes (n 
10), and the group with smaller tumor volumes (n  20, four
censored). The median survival months of the large and the
small volume groups were 10.2 and 21.5, respectively. Pa-
tients in the small volume group had a slight tendency to
survive longer (p  0.07) (Figure 4A). Categorizing patients
into two groups above and below the median volume showed
no significant survival differences (p  0.36).
Thirteen patients with low radiologic TNM stage (stage
I, n  3; stage II, n  10) had median volume of 290 cm3
(range, 61 cm3–1447 cm3); whereas seventeen patients with
high radiologic TNM stage (stage III, n  12; stage IV,
n  5) had median volume of 596 cm3 (range, 84 cm3–2108
cm3). Patients with high stage had significantly larger tumor
volume than those with low stage (p  0.05). Twenty-three
patients had postoperative staging. There was no significant
volumetric difference between the low stage group (n  8)
and the high stage group (n  15, p  0.59).
Early Follow-up Analysis
Among the 27 patients who had at least one fol-
low-up CT scan performed after two cycles of chemother-
apy, the changes of MPM volumes were computed.
Change of tumor volume was significantly associated with
overall survival (hazard ratio: 1.94 [95% confidence inter-
val, 1.05–3.60], p  0.04). The more tumor growth oc-
curred, the less likely was a patient to survive and vice
versa. Twenty-five patients had modified RECIST mea-
surements obtained from the clinical trials. The relative
change between baseline and follow-up showed no signif-
icant association with overall survival (hazard ratio: 1.06
[95% confidence interval, 0.96 –1.16], p  0.25). The
predictive ability of the volumetric measurement (C-in-
dex  0.74) is significantly higher than that of the modi-
fied RECIST measurement (C-index  0.5, p  0.05).
A significant difference in survival was found be-
tween the group of patients who had an increase in tumor
FIGURE 2. Computer segmentation of tumor corrected
by radiologist. A, computer result on original image with
suboptimal segmentation and inclusion of other tissues
(arrows). B, manual correction on computer result. C and
D, 3D rendering of the baseline alignant pleural mesothe-
lioma (MPM) volume (596 cc) and the first follow-up
MPM volume (208 cc).
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volume after chemotherapy (n  10) and the group
who had a decrease in tumor volume (n  17, p  0.03)
(Figure 4B). The median survival of the former was 11.5
months, whereas the median survival of the latter was 18.1
months.
Interobserver Variation
Both baseline and follow-up measurements had good
reproducibility between the two radiologists, whereas there
was a slight decline in reproducibility for the percent change
from baseline to follow-up, as shown in Table 1:
DISCUSSION
Many patients with MPM present with disease confined
to the ipsilateral pleural. As such, resection by pleurectomy or
extrapleural pneumonectomy is often considered when a
patient is adequately fit to tolerate surgery and chest wall
invasion by tumor is not apparent. Combined modality ther-
apy, incorporating chemotherapy, and radiotherapy along
with the surgery have also been studied now by several
FIGURE 3. Overall survival curve.
FIGURE 4. Survival analysis of baseline and early follow-up. A, patients with small MPM volume in baseline tends to survival
longer (p  0.07). B, patients whose MPM volume decreased in early follow-up and longer survival (p  0.03).
TABLE 1. Concordance Correlation Coefficient (CCC)
Between Two Radiologists
CCC (95% CI)
Baseline volume 0.993 (0.988–0.998)
Follow-up volume 0.991 (0.984–0.997)
Change from baseline to follow-up 0.872 (0.821–0.922)
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groups. This aggressive approach remains controversial,
however, because recurrence develops quickly and survival
remains poor.
Because of its irregular shape and circumferential-axial
growth pattern, MPM size cannot be appropriately assessed
for response to therapy using the conventional RECIST and
World Health Organization criteria.11–13,15,28 Furthermore, the
measurement sites are hard to locate reproducibly on serial
CT scans, causing considerable variations in the measure-
ments.29,30 Although criteria based on the unidimensional and
bidimensional methods are proposed and applied to clinical
trials,31–33 and the modified RECIST showed improved re-
sponse assessment in larger patient number,14 these intrinsic
limitations still remain.
In this study, we attempted to investigate whether the
tumor volume, or change in tumor volume of MPM calcu-
lated on serial CT scans could be useful in the assessment of
tumor response to chemotherapy and the prediction of patient
survival. If tumor volume can be reliably estimated from CT
images, volume change would more accurately reflect true
tumor size change and would likely better indicate tumor
response to therapy.
We found that changes in tumor volumes between
baseline and follow-up performed at two cycles after chemo-
therapy were significantly associated with survival, whereas
changes in modified RECIST measurements at the same time
interval did not show such a correlation. In addition, patients
with reduced tumor volume at the first follow-up were shown
to have longer survival than those patients with increased
tumor volume. This corresponds to the overall results from
the multicenter induction chemotherapy study.4 In that trial,
radiologic response to chemotherapy was the best predictor of
survival, even compared with other well established prognos-
tic factors such as histologic subtype, gender, stage, and
lymph node involvement.
Calculating MPM volume is impractical without the aid
of a computer due to time constraints, interobserver variabil-
ity, and large number of slices. In this study, our semiauto-
matic computer method assisted the radiologist in the tumor
volume measurement. We were able to separate MPM from
its surrounding anatomic structures including (but not limited
to) chest wall, mediastinum, and liver, using a sequential
organ dissection strategy, that has previously been described
with the gradient vector flow snake for the liver extraction20
and the chest-rib interpolation technique for the chest wall
extraction.18 One advantage of this algorithm was to use the
specific model/knowledge of the organ to identify the edge
between the organ and tumor, which was otherwise difficult
to be delineated due to similar densities of the two.
In clinical practice, as in our study, we expect the
computer method to be integrated into a user-friendly system
that allows operator to run the software and radiologist to
review computer results (i.e., tumor contours) and correct any
result if it is not satisfactory. The edited result will be served
as the “final result” to calculate the tumor volumes and
volume changes for assessing tumor response to therapy and
predicting patient survival.
Our prognostic baseline volume-survival result was
different from the previously reported data by Pass et al.17 In
our study, the threshold for categorizing large-volume and
small-volume disease was 618 cm3, rather than the 100 cm3
as reported in the experiments of Pass et al. One possible
reason for the discrepancy between our threshold and Pass et
al. is that the criteria for patient registration differed in the
two studies. We did not set a prerequisite for tumor thickness
or tumor volume when selecting patients, but Pass et al.
included only patients who had a maximum tumor thickness
of 5 mm after debulking. As it was, the difference in survival
between the two groups approached statistical significance,
suggesting the possibility of a relationship between preoper-
ative MPM volume and patient survival.
We used a different classification system (“increase” or
“decrease”) than the RECIST and modified-RECIST criteria,
both of which use a threshold of 30% to define a therapeutic
response. The outcome of the two groups in our experiments
showed significant difference, suggesting that soon after
chemotherapy the volume might begin to change in different
directions (increase or decrease) and predict patient survival.
However, this needs to be further investigated by a large
dataset of patients and accounting for measurement variables
such as repeatability, interobserver variation, and partial vol-
ume artifact.
Positron emission tomography (PET) with the radio-
pharmaceutical agent 18F-fluorodeoxyglucose (FDG) has
been increasingly applied in MPM to assess therapy response
and shown promise.8,34–38 Maximum standard uptake value
(SUVmax) on
18F-FDG PET is the most commonly used
measurement to evaluate treatment response in mesotheli-
oma.8 Studies have shown that baseline SUVmax, a combina-
tion of SUVmax and histology, and change of SUVmax in early
follow-up scan correlate well with patient survival.34,35,37
Total lesion glycolysis (the total metabolic activity inside the
tumor volume)39 and total glycolytic volume (a measure of
the composite of volume and total metabolic activity) are
found superior to SUVmax and modified RECIST in assessing
tumor response and/or predicting patient’s survival.36 How-
ever, preliminary data from gastrointestinal stromal tumor
study showed that by lowering the RECIST cut-off scale and
combining tumor density change, CT performed equally well
to FDG PET as a biomarker for response assessment.40 In
addition, the confounding factor of talc pleurodesis also
results in an increased and persistent uptake of FDG. PET
imaging is more expensive, less accessible and has lower
spatial resolution compared with the widely used CT. It
would benefit the patients and reduce cost if MPM volumes
and their changes after treatment on CT scans could be
proven useful in the prediction of patient survival and accu-
rately and practically measured.
Our study had some limitations. First, only tumor
volume and volume change were considered to predict sur-
vival. Other clinical factors such as histology, pathologic
stage, gender, asbestos exposure, smoking, symptoms, and
laterality can also affect patient survival.41 About half of the
patients in this study had talc pleurodesis, and it is difficult to
determine the effect this would have on the results. Nonethe-
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less, in the majority of cases, the pleural rind was readily
apparent on CT imaging, and the effects of talc pleurodesis
would not impact the measurements in a significant way. Our
results might have been affected by observer bias and heter-
ogeneous thick slice thicknesses. Finally, the study popula-
tion was relatively small making it difficult to achieve appro-
priate statistical significance for several results as indicated
earlier. Our findings need to be validated in future MPM
clinical trials with a large patient population.
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